Samarth Kulkarni - Net Worth and Insider Trading
Samarth Kulkarni Net Worth
The estimated net worth of Samarth Kulkarni is at least $16 Million dollars as of 2024-11-05. Samarth Kulkarni is the CEO of CRISPR Therapeutics AG and owns about 312,162 shares of CRISPR Therapeutics AG (CRSP) stock worth over $16 Million. Details can be seen in Samarth Kulkarni's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Samarth Kulkarni has not made any transactions after 2024-10-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Samarth Kulkarni
Samarth Kulkarni Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Samarth Kulkarni owns 4 companies in total, including CRISPR Therapeutics AG (CRSP) , Repare Therapeutics Inc (RPTX) , and Black Diamond Therapeutics Inc (BDTX) among others .
Click here to see the complete history of Samarth Kulkarni’s form 4 insider trades.
Insider Ownership Summary of Samarth Kulkarni
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CRSP | CRISPR Therapeutics AG | 2024-10-14 | Chief Business Officer |
RPTX | Repare Therapeutics Inc | 2020-06-18 | director |
BDTX | Black Diamond Therapeutics Inc | 2020-01-29 | director |
2021-05-27 | director |
Samarth Kulkarni Latest Holdings Summary
Samarth Kulkarni currently owns a total of 1 stock. Samarth Kulkarni owns 312,162 shares of CRISPR Therapeutics AG (CRSP) as of October 14, 2024, with a value of $16 Million.
Latest Holdings of Samarth Kulkarni
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
CRSP | CRISPR Therapeutics AG | 2024-10-14 | 312,162 | 49.68 | 15,508,208 |
Holding Weightings of Samarth Kulkarni
Samarth Kulkarni Form 4 Trading Tracker
According to the SEC Form 4 filings, Samarth Kulkarni has made a total of 26 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years, including 0 buys and 26 sells. The most-recent trade in CRISPR Therapeutics AG is the sale of 4,293 shares on October 14, 2024, which brought Samarth Kulkarni around $198,680.
Insider Trading History of Samarth Kulkarni
- 1
Samarth Kulkarni Trading Performance
Samarth Kulkarni Ownership Network
Ownership Network List of Samarth Kulkarni
Ownership Network Relation of Samarth Kulkarni
Samarth Kulkarni Owned Company Details
What does CRISPR Therapeutics AG do?
Who are the key executives at CRISPR Therapeutics AG?
Samarth Kulkarni is the Chief Business Officer of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include General Counsel and Secretary James R. Kasinger , Chief Financial Officer Raju Prasad , and Chief Medical Officer Phuong Khanh Morrow .
CRISPR Therapeutics AG (CRSP) Insider Trades Summary
Over the past 18 months, Samarth Kulkarni made 9 insider transaction in CRISPR Therapeutics AG (CRSP) with a net sale of 179,630. Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 6,949 shares made by James R. Kasinger , a net sale of 3,524 shares made by Raju Prasad , and a net sale of 3,366 shares made by .
In summary, during the past 3 months, insiders sold 5,382 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 5,382 shares. During the past 18 months, 193,469 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 193,469 shares.
CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.
CRISPR Therapeutics AG Insider Transactions
Samarth Kulkarni Mailing Address
Above is the net worth, insider trading, and ownership report for Samarth Kulkarni. You might contact Samarth Kulkarni via mailing address: C/o Crispr Therapeutics Ag, 200 Sidney Street, Cambridge Ma 02139.